

A TARGETED APPROACH TO TAMING NF1–ASSOCIATED TUMORS

Navigating the Child Neurologist's Role in an Evolving Treatment Calculus

cec oncology

Presented by Creative Educational Concepts, LLC

Supported through an independent educational grant from AstraZeneca.

Disclaimer

- This slide deck in its original and unaltered format is for educational purposes and is current as of the date of this presentation. All materials contained herein reflect the views of the faculty, and not those of Creative Educational Concepts, Inc. or the commercial supporter(s).
- Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for specific patient management.
- Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review or any applicable manufacturer's product information, and comparison with recommendations of other authorities.
- **Usage Rights:** This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts, Inc. Additional terms and conditions may apply.

Presented by

cec oncology

Supported through an independent educational grant from AstraZeneca.

Learning Objectives

- Review recently updated NF1 diagnostic criteria and recognized established NF1 clinical manifestations to promote earlier detection and treatment initiation, especially in pediatric patients.
- Describe the genetic genesis and multifaceted pathophysiology of NF1, with a focus on the neurological morbidity and historical intractability of symptomatic, inoperable plexiform neurofibromas.
- Evaluate traditional NF1-associated plexiform neurofibroma treatment modalities, including surgery, radiation, and surveillance, and emphasize how targeted medical therapies are poised to bridge crucial chasms in care.
- Appraise completed and ongoing clinical trial data for MEK inhibitors and other novel targeted therapies being studied in NF1-associated tumors, with an emphasis on current treatment recommendations and approved indications.
- Discuss the pivotal placement of the pediatric neurologist on the multidisciplinary NF1 treatment team, and design real-world, evidence-based treatment plans using targeted therapies for NF1-associated tumors.

Expert Faculty



Activity Chair
Verena Staedtke, MD, PhD
Associate Professor of Neurology
Director of the Pediatric NF Program
Johns Hopkins Comprehensive
Neurofibromatosis Center
Johns Hopkins School of Medicine

Expert Panelist
Michael J. Fisher, MD
Director of the NF Program
Hubert J.P. and Anne Faulkner
Schoemaker Endowed Chair
in Pediatric Neuro-Oncology
The Children's Hospital of Philadelphia

Expert Panelist
Nicole Ullrich, MD, PhD
Associate Professor of Neurology
Director, Neurologic Neuro-Oncology
Associate Director, Neurofibromatosis
Clinical Trials Program
Harvard & Boston Children’s Hospital

This activity is accredited for 1.5 CE credit hour for physicians. Non-physicians may request a certificate of participation.

Instructions for completing the evaluation and requesting CE credit will be provided at the end of this webinar.

Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

PLANNERS

Verena Staedtke, MD, PhD–has no relevant financial relationships to disclose in relation to the content of this activity.

Bryan C. Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

PRESENTERS

Verena Staedtke, MD, PhD–has no relevant financial relationships to disclose in relation to the content of this activity.

Michael J. Fisher, MD–has disclosed that he is a consultant for AstraZeneca and SpringWorks. He receives Grant/Research support from AstraZeneca and Array BioPharma Inc.

Nicole Ullrich, MD, PhD–has disclosed that she is a consultant for Peer Review Institute for Medical Education.

PEER REVIEWER

Miriam Bornhorst, MD—has disclosed she is a consultant for AstraZeneca.

E-syllabus and Questions

An electronic version of the handout and program resources are available for download at:
https://www.ceconcepts.com/NF1-CNS

? ***Have a question for the Faculty?***

Use the chat feature in Zoom to ask the faculty your questions.